sp taking another bashing, page-2

if you can hold for the medium to long term, the current SP is an absolute gift in my opinion.

Bought a lot of shares the day post ODAC announcement - in at 29 and will not be selling for under $1.

my only concern is the need for another capital raising.

the study "incomplete" issue and vial size issue are not really major issues. CXS can submit further data to support efficacy claims if required. the biggest issue is still with the T315I mutation diagnostic that must be correlated to their NDA.

make the most of this investor impatience and fear.